Conference Coverage

Prolia tops risedronate at 2 years in steroid-induced osteoporosis

Publish date: July 10, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

SOURCE: Saag KG et al. Ann Rheum Dis. 2018;77(Suppl 2):218. Abstract OP0345.

Pages

Recommended Reading

Time to take the fear out of the hormone therapy conversation
MDedge Endocrinology
VIDEO: Dr. Andrew Kaunitz’s top lessons from NAMS 2017
MDedge Endocrinology
Use of opioids, SSRIs linked to increased fracture risk in RA
MDedge Endocrinology
Transgender women on HT have lower bone density, more fat mass than men
MDedge Endocrinology
Spine fracture risk may be increased in IBD patients
MDedge Endocrinology
Original research expands at AACE 2018
MDedge Endocrinology
AACE 2018: A dream team of presenters
MDedge Endocrinology
VIDEO: BMI helps predict bone fragility in obese patients
MDedge Endocrinology
FDA approves Prolia for glucocorticoid-induced osteoporosis
MDedge Endocrinology
What underlies post–bariatric surgery bone fragility?
MDedge Endocrinology